Coronary/Structural Heart

Cordis-X Makes Strategic Investment in Adient Medical, Developer of First Fully Absorbable Inferior Vena Cava (IVC) Filter

Signals continued investment in accelerated cardiovascular technology development MENLO PARK, Calif., June 14, 2022 /PRNewswire/ — Cordis-X today announced an $11.5 million Series F investment in Adient Medical, maker of a next-generation absorbable inferior vena cava (IVC) filter that provides protection against pulmonary embolisms (PE). The device is designed to avoid well-documented risks of perforation, migration, fracture, […]

Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome

Type B meeting scheduled with FDA Division of Cardiology and Nephrology Company plans to discuss new clinical data that may inform a potential NDA submission BOSTON, June 14, 2022 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, […]

Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas

Pediatric Segment Growth Continues at 36% CAGR MINNEAPOLIS, June 14, 2022 (GLOBE NEWSWIRE) — Improving access to life-saving fluid management therapies is a commitment by which Nuwellis, Inc. (Nasdaq: NUWE) stands. The company today announced its Aquadex SmartFlow® system is now available at two new pediatric hospitals in Florida and Arkansas. “By […]

Vascular Quality Initiative (SVS VQI) Announces the Expansion of Medicare Coverage to Standard Surgical Risk Patients within their TCAR Surveillance Project

CHICAGO–(BUSINESS WIRE)–The Society for Vascular Surgery® Vascular Quality Initiative® (SVS VQI), a nonprofit organization dedicated to improving the quality of vascular care within hospitals and outpatient facilities, announces that the Centers for Medicare and Medicaid Services (CMS) has expanded coverage for Transcarotid Artery Revascularization (TCAR) to include standard surgical risk patients within the VQI […]

Fauna Bio’s Comparative Genomics Approach Finds New Compounds for Heart and Lung Diseases

Partnerships with top institutions move leading candidates into pre-clinical evaluation; platform updates enable discovery of new targets EMERYVILLE, Calif., June 14, 2022 /PRNewswire/ — Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is […]

HeartLab Unveils Pulse 2.0, An Efficient Cardiology Imaging Platform, at ASE Scientific Sessions 2022

Pulse is a cloud platform for cardiac imaging that streamlines reporting workflows to help cardiologists be more efficient AUCKLAND, New Zealand, June 13, 2022 /PRNewswire/ — HeartLab, the creator of Pulse — a cloud platform to help clinicians streamline reporting workflows — today announced the US launch of Pulse 2.0 at the American Society […]

Genesis Foundation and SBI Foundation together save a 2-month-old baby from heart failure

THANE, India, June 13, 2022 /PRNewswire/ — Two–month–old, Sakshi (name changed) had a hole in her heart called the Aorta Pulmonary Window. With extreme respiratory distress, the child would not have survived infancy if she had not received timely treatment, with financial support from SBI Foundation, through Genesis Foundation. With a weight of 2.9 kilograms, […]

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

LEXINGTON, Mass., June 13, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical […]

Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

Echocardiographic Data Show Treatment with Aficamten for 10 Weeks Results In Improved Cardiac Structure, Myocardial Relaxation and Mitral Valve Mechanics SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from a new analysis of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) […]

Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor

This randomized, placebo-controlled Phase II clinical study with TOTUM•070 achieved its objective of reducing LDL cholesterol (primary endpoint) and confirmed the very good tolerance of this active substance. As early as 3 months of supplementation, the results showed a significant reduction in blood levels of LDL cholesterol (-13%) and triglycerides […]